Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma...

Full description

Bibliographic Details
Main Authors:	Marco Banini, Viola Salvestrini, Alessandra Vultaggio, Margherita Perlato, Valentina Mecheri, Cecilia Cerbai, Vieri Scotti, Andrea Matucci, Monica Mangoni, Lorenzo Livi, Pierluigi Bonomo
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Current Oncology
Subjects:	cutaneous squamous cell carcinoma Cemiplimab drug-related infusion reaction drug desensitization
Online Access:	https://www.mdpi.com/1718-7729/30/7/491

Similar Items

Successful desensitization with 5-fluorouracil in a patient who developed anaphylaxis after 5-fluorouracil infusion
by: Mehmet Erdem Çakmak, et al.
Published: (2024-08-01)

Combination of Cemiplimab and Radiotherapy in Advanced Squamous Cell Carcinoma
by: André Aparício Martins, et al.
Published: (2025-01-01)

The increasing role of the allergist in the management of infusion reactions at the Oncology Infusion Center
by: Julián Borrás Cuartero, et al.
Published: (2024-12-01)

The experiences of ferric carboxymaltose desensitization and provocation
by: Fatma Dindar Çelik, MD, et al.
Published: (2025-02-01)

Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)
by: Amarnath Challapalli, et al.
Published: (2024-07-01)

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
by: Goar Egoryan, et al.
Published: (2024-12-01)

Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations
by: Gozde Koycu Buhari, MD, et al.
Published: (2024-01-01)

Temporal Modulation of Drug Desensitization Procedures
by: Razvan Costin Stan
Published: (2022-02-01)

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
by: Ferdinando Costabile, et al.
Published: (2023-09-01)

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
by: Kosei Hasegawa, et al.
Published: (2024-09-01)

DRESS syndrome due to anti-TB drugs: A complex case with successful re-desensitization of group A drugs
by: Cristian Morán-Mariños, et al.
Published: (2024-04-01)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
by: Maria Boziou, et al.
Published: (2023-07-01)

Distinct transcriptomic and metabolomic profiles characterize NSAID-induced urticaria/angioedema patients undergoing aspirin desensitization
by: Tay, Sen Hee, et al.
Published: (2023)

Desensitization to allopurinol in patients with gout and cutaneous reactions /
by: Fam, Adel G.

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
by: Domenico Mallardo, et al.
Published: (2023-02-01)

Two-year follow-up after drug desensitization in mucopolysaccharidosis
by: Federico Spataro, et al.
Published: (2024-12-01)

Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience
by: Döne Gülçin Unutmaz Erkaya, et al.
Published: (2024-10-01)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
by: T. Van Meerhaeghe, et al.
Published: (2022-10-01)

Feedback control of drug infusion system /
by: 280584 Aw, Sei Howe, et al.
Published: (2009)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
by: Tae-Jun Jeong, et al.
Published: (2022-12-01)

Application of a multifunctional chemotherapy infusion device for reducing antineoplastic drug extravasation
by: Li-Hua Yang, et al.
Published: (2025-03-01)

Stability Analysis in a New Model for Desensitization of Allergic Reactions Induced by Chemotherapy of Chronic Lymphocytic Leukemia
by: Rawan Abdullah, et al.
Published: (2023-07-01)

Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty<sup>®</sup>) COVID-19 Vaccination Successfully Treated with Cemiplimab
by: Proietti Ilaria, et al.
Published: (2024-08-01)

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
by: T. Van Meerhaeghe, et al.
Published: (2023-01-01)

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
by: Anna Passarelli, et al.
Published: (2023-12-01)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
by: Nerina Denaro, et al.
Published: (2023-09-01)

Feedback control of drug infusion system [electronic resource] /
by: 280584 Aw, Sei Howe
Published: (2009)

Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands
by: Maartje W. Rohaan, et al.
Published: (2023-01-01)

Induction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report
by: Elizabeth G. Thayer, et al.
Published: (2024-10-01)

Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital
by: Tunakan Dalgic C, et al.
Published: (2023-07-01)

Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
by: Tibor A. Zwimpfer, et al.
Published: (2024-01-01)

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
by: Yitian Lang, et al.
Published: (2024-02-01)

Eye Movement Desensitization and Reprocessing (EMDR) as a Neurorehabilitation Method
by: Afsaneh Zarghi, et al.
Published: (2013-01-01)

Importance of Desensitization for Autistic Children in Dental Practice
by: Eva Martínez Pérez, et al.
Published: (2023-04-01)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
by: Mager L, et al.
Published: (2023-08-01)

One- versus 2-day aspirin desensitization in aspirin exacerbated respiratory disease: A quality improvement project
by: Emily Gansert, BS, et al.
Published: (2023-11-01)

Successful Oral Levothyroxine Desensitization in a Patient with Severe Hypothyroidism Post Radioactive Iodine Therapy
by: Yi Jiang Chua, et al.
Published: (2022-07-01)

Methodological Aspects of Cognitive Rehabilitation with Eye Movement Desensitization and Reprocessing (EMDR)
by: Afsaneh Zarghi, et al.
Published: (2013-02-01)

Non-clinical vascular infusion technology /
by: 582533 Green, Owen P., et al.
Published: (2014)

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context
by: Karlijn Verkerk, et al.
Published: (2024-04-01)